SI0814783T1 - Multiple enotske šumeče dozirne oblike, ki obsegajo inhibitor protonske črpalke - Google Patents

Multiple enotske šumeče dozirne oblike, ki obsegajo inhibitor protonske črpalke

Info

Publication number
SI0814783T1
SI0814783T1 SI9630657T SI9630657T SI0814783T1 SI 0814783 T1 SI0814783 T1 SI 0814783T1 SI 9630657 T SI9630657 T SI 9630657T SI 9630657 T SI9630657 T SI 9630657T SI 0814783 T1 SI0814783 T1 SI 0814783T1
Authority
SI
Slovenia
Prior art keywords
protonpump
inhibitor
dosage forms
multiple unit
effervescent dosage
Prior art date
Application number
SI9630657T
Other languages
English (en)
Inventor
Per Johan Lundberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0814783(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI0814783T1 publication Critical patent/SI0814783T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI9630657T 1996-01-08 1996-12-20 Multiple enotske šumeče dozirne oblike, ki obsegajo inhibitor protonske črpalke SI0814783T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9600073A SE512835C2 (sv) 1996-01-08 1996-01-08 Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
PCT/SE1996/001738 WO1997025030A1 (en) 1996-01-08 1996-12-20 Multiple unit effervescent dosage forms comprising protonpump inhibitor
EP96944727A EP0814783B1 (en) 1996-01-08 1996-12-20 Multiple unit effervescent dosage forms comprising protonpump inhibitor

Publications (1)

Publication Number Publication Date
SI0814783T1 true SI0814783T1 (sl) 2004-04-30

Family

ID=20400971

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630657T SI0814783T1 (sl) 1996-01-08 1996-12-20 Multiple enotske šumeče dozirne oblike, ki obsegajo inhibitor protonske črpalke

Country Status (33)

Country Link
US (1) US6132770A (sl)
EP (1) EP0814783B1 (sl)
JP (1) JP4638561B2 (sl)
KR (1) KR100459363B1 (sl)
CN (1) CN100335043C (sl)
AR (1) AR005280A1 (sl)
AT (1) ATE251451T1 (sl)
AU (1) AU712325B2 (sl)
BR (1) BR9607367A (sl)
CA (1) CA2214027C (sl)
CZ (1) CZ280797A3 (sl)
DE (1) DE69630286T2 (sl)
DK (1) DK0814783T3 (sl)
EE (1) EE9700189A (sl)
ES (1) ES2208775T3 (sl)
HR (1) HRP970005A2 (sl)
HU (1) HUP0000976A3 (sl)
ID (1) ID15819A (sl)
IL (1) IL121653A (sl)
IS (1) IS4551A (sl)
MX (1) MX9706768A (sl)
NO (1) NO319999B1 (sl)
NZ (1) NZ325978A (sl)
PL (1) PL322161A1 (sl)
PT (1) PT814783E (sl)
SE (1) SE512835C2 (sl)
SI (1) SI0814783T1 (sl)
SK (1) SK117197A3 (sl)
TN (1) TNSN97002A1 (sl)
TR (1) TR199700918T1 (sl)
WO (1) WO1997025030A1 (sl)
YU (1) YU70196A (sl)
ZA (1) ZA9610939B (sl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
WO1999029299A1 (en) * 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel suppository form comprising an acid-labile active compound
EP1056456A4 (en) * 1998-01-30 2006-10-25 Sepracor Inc R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
DK1561458T3 (da) * 1998-07-28 2010-10-25 Takeda Pharmaceutical Hurtigt henfaldende fast middel
MXPA01009934A (es) * 1999-03-29 2002-06-21 American Home Prod Sistema de recubrimiento.
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
PT1341528E (pt) 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7138399B2 (en) 2002-03-27 2006-11-21 Altana Pharma Ag Alkoxypyridine-derivatives
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
US20060177506A1 (en) * 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1670798A1 (en) * 2003-10-01 2006-06-21 Altana Pharma AG Aminopyridine-derivatives as inductible no-synthase inhibitors
AU2004276015A1 (en) 2003-10-01 2005-04-07 Altana Pharma Ag Imidazopyridine-derivatives as inductible no-synthase inhibitors
WO2005030770A1 (en) 2003-10-01 2005-04-07 Altana Pharma Ag Imidazopyridine-derivatives as inducible no-synthase inhibitors
JP2007507463A (ja) 2003-10-01 2007-03-29 アルタナ　ファルマ　アクチエンゲゼルシャフト 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
CN101242811B (zh) * 2005-08-15 2015-06-17 雅培实验室有限公司 酸不稳定性药物的控释药物组合物
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US7776831B2 (en) 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP1834634A3 (en) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Pharmaceutical multiple-unit composition
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
EP2044932A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Mechanical protective layer for solid dosage forms
BR112017005362A2 (pt) 2014-09-17 2018-01-23 Steerlife India Private Ltd composição, forma de dosagem sólida oral, processo para preparação de grânulos efervescentes porosos, processador de parafuso duplo, e, grânulos efervescentes porosos.
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN112574835A (zh) * 2019-09-30 2021-03-30 埃科莱布美国股份有限公司 泡腾片清洁剂及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) * 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
WO1986007348A1 (en) * 1985-06-03 1986-12-18 Hughes Aircraft Company Method for introducing dopants in optical fiber preforms
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
KR930017902A (ko) * 1992-02-14 1993-09-20 알베르투스 빌헬무스 요아네스 째스트라텐 살충제 화합물 및 그의 제조 방법
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
KR970011587B1 (ko) * 1992-07-31 1997-07-12 삼성전자 주식회사 Mac 시스템의 프레임 싱크 검출회로
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
JP3017906B2 (ja) * 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US5798120A (en) * 1993-10-12 1998-08-25 Tokyo Tanabe Company Limited Enteric granule-containing tablets
GB2285989A (en) * 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare

Also Published As

Publication number Publication date
NO974051D0 (no) 1997-09-03
SE9600073D0 (sv) 1996-01-08
IL121653A0 (en) 1998-02-08
TR199700918T1 (xx) 1997-11-21
BR9607367A (pt) 1997-12-30
HUP0000976A3 (en) 2000-12-28
NO974051L (no) 1997-10-15
HUP0000976A2 (hu) 2000-11-28
AR005280A1 (es) 1999-04-28
PT814783E (pt) 2004-02-27
EP0814783A1 (en) 1998-01-07
IS4551A (is) 1997-08-25
ES2208775T3 (es) 2004-06-16
EE9700189A (et) 1998-02-16
ID15819A (id) 1997-08-14
NO319999B1 (no) 2005-10-10
SK117197A3 (en) 1998-05-06
JP4638561B2 (ja) 2011-02-23
DE69630286T2 (de) 2004-07-22
PL322161A1 (en) 1998-01-19
ATE251451T1 (de) 2003-10-15
WO1997025030A1 (en) 1997-07-17
CN1183716A (zh) 1998-06-03
CA2214027A1 (en) 1997-07-17
IL121653A (en) 2001-08-08
ZA9610939B (en) 1997-07-08
HRP970005A2 (en) 1998-04-30
CN100335043C (zh) 2007-09-05
CZ280797A3 (cs) 1998-03-18
KR19980702830A (ko) 1998-08-05
YU70196A (sh) 1999-07-28
NZ325978A (en) 1999-02-25
US6132770A (en) 2000-10-17
SE512835C2 (sv) 2000-05-22
AU712325B2 (en) 1999-11-04
JPH11501951A (ja) 1999-02-16
TNSN97002A1 (fr) 2005-03-15
EP0814783B1 (en) 2003-10-08
KR100459363B1 (ko) 2005-01-17
DK0814783T3 (da) 2004-01-26
AU1324297A (en) 1997-08-01
MX9706768A (es) 1997-11-29
SE9600073L (sv) 1997-07-09
CA2214027C (en) 2006-09-05
DE69630286D1 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
SI0814783T1 (sl) Multiple enotske šumeče dozirne oblike, ki obsegajo inhibitor protonske črpalke
GB2318129B (en) Dispenser
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
EP0835109A4 (en) PYRIDINONE-BASED THROMBIN INHIBITORS
ZA98376B (en) Sulfamide-metalloprotease inhibitors
HUP9901454A3 (en) Dosage form of ibuprofen
GB2321641B (en) Sulfamide-metalloprotease inhibitors
ZA97939B (en) Dispenser
PL331803A1 (en) Bidonoric metaloprotease inhibitors
IL123268A0 (en) PEP inhibitor
HU9503783D0 (en) Squvalen syntetase inhibitors
AU131684S (en) Dispenser
IL134491A0 (en) Dosage device
DE69523450D1 (en) Inhibitor
CA78160S (en) Tablet dispenser
GB9719261D0 (en) Dosage forms
GB9601787D0 (en) Inhibitors
GB9623742D0 (en) Inhibitors
HUP9602759A3 (en) Antiseptic tablet
GB9615741D0 (en) Tablet dispenser
ZA978663B (en) Tablet dispenser
GB9717893D0 (en) Inhibitor
GB9707219D0 (en) Inhibitor
AU131608S (en) Dispenser
PL104029U1 (en) Dispenser